LEO Pharma’s PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition

1 February 2010

LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company’s lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.

Findings from the REGION Ib study in body AK support results from the earlier REGION-I trial, a study evaluating PEP005 for the treatment of AK on the head reported in December 2009.

AK is a pre-cancerous skin condition that if left untreated, can lead to the development of skin cancer.

"PEP005 is a recent addition to LEO Pharma’s robust dermatology pipeline. We could not be happier with the preliminary findings that suggest PEP005 may be a promising new treatment option for patients with this type condition, a pre-cursor to skin cancer," said Lars Olsen, Executive Vice President for Research & Development, LEO Pharma.

Cryotherapy, a procedure in which the surface skin lesions are frozen, is currently the most common treatment alternative for AK. It is used as the sole approach in approximately 75% of treatments for AK lesions, and in combination with topical drugs in approximately 9% of treatments. The American Academy of Dermatology reports that 40 percent of cases of squamous cell carcinoma begin as AKs.

Approximately 250 patients were enrolled in the REGION Ib study, which evaluated the use of a 0.05% concentration of PEP005 Gel applied daily as monotherapy for two consecutive days to AK lesions on non-head locations.

PEP005 Gel demonstrated a favorable safety profile and was well tolerated; side effects were consistent with those seen in Phase II studies. There were no drug-related serious adverse events reported. The trials were initiated and run by Peplin, Inc., acquired by LEO Pharma in September 2009.

Results from REGION I and Ib will be presented at an upcoming meeting of the American Academy of Dermatology.

LEO Pharma expects to file for regulatory approval of the treatment in the U.S. and Europe in 2011.

About Actinic Keratosis
Actinic keratosis (AK) is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated. The number of AK patients is both large and rapidly growing, and AK is a serious health problem.

About LEO Pharma
Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of Dermatology and Critical Care Medicine. Wholly owned by The LEO Foundation, the company is headquartered in Ballerup, Denmark, outside of Copenhagen, and is represented in more than 90 countries worldwide. Employees number more than 3,000, with 550 scientists and specialists working to develop new chemical entities.

With a strong portfolio of approved products and a robust pipeline of treatments in development for conditions including psoriasis, eczema and actinic (solar) keratosis, LEO Pharma is one of the leading dermatology companies in the U.S. and the world.

For more information about LEO Pharma, visit www.leo-pharma.com.

Media Contact
Andreas Lohmann
Corporate Vice President, Development
LEO Pharma
Tel.: +45 4494 5888

Pamela Lippincott
Zeno Group
+1 202-239-4350 

 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.